In a historic move, the U.S. Food and Drug Administration (FDA) has given its approval to Hemgenix (etranacogene dezaparvovec), a revolutionary gene therapy designed to combat Hemophilia B, a genetic bleeding disorder characterized by deficient clotting Factor IX. This breakthrough comes as a beacon of hope for individuals grappling with this condition, particularly those who have experienced life-threatening hemorrhages or frequent spontaneous bleeding episodes. Hemgenix, delivered as a single intravenous infusion, employs adeno-associated virus vectors to introduce a Factor IX gene into the liver, thereby enhancing Factor IX production and diminishing the occurrence of bleeding episodes.
Hemophilia B, which occurs predominantly in men, arises due to inadequate Factor IX levels necessary for blood clotting. Those affected often endure prolonged and severe bleeding, even post-injury or surgery, leading to severe complications like internal organ and joint bleeding. The prevalence of Hemophilia B in the population is about one in 40,000; Hemophilia B represents about 15% of patients with hemophilia. Notably, while many women who carry the genetic mutation are asymptomatic, between 10-25% experience mild symptoms, with rare cases of moderate to severe symptoms.
Conventionally, managing Hemophilia B necessitates regular intravenous infusions of Factor IX replacement products to maintain clotting factor levels, prevent bleeding, and promote healing. However, Hemgenix marks a paradigm shift, offering a one-time gene therapy solution that addresses the root cause of the disorder. The safety and effectiveness of Hemgenix were evaluated in two studies of 57 adult men 18 to 75 years of age with severe or moderately severe Hemophilia B. Encouragingly, results demonstrated reduced annualized bleeding rates, increased Factor IX activity levels, and diminished reliance on routine Factor IX replacement prophylaxis, with a remarkable 54% reduction in bleeding rates compared to baseline.
While the approval of Hemgenix is cause for celebration, it is crucial to monitor patients for potential adverse reactions. Common side effects associated with this gene therapy include liver enzyme elevations, mild infusion-related reactions, headaches, and flu-like symptoms. Consequently, diligent surveillance for adverse infusion reactions and liver enzyme elevations (transaminitis) in patients' blood is imperative.
The FDA's green light for Hemgenix signifies a monumental advancement in the treatment landscape for Hemophilia B, offering renewed hope and a more efficient therapeutic option for those living with this challenging condition. With its potential to alleviate the necessity for regular Factor IX infusions and mitigate the associated health risks, Hemgenix embodies a significant stride towards enhancing the quality of life for individuals affected by Hemophilia B.
Source: Press Release. United States Food and Drug Administration. "FDA Approves First Gene Therapy to Treat Adults with Hemophilia B". https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b. [Date accessed: 22/11/22].
Edited by: Adhitya Balachander
留言